228 related articles for article (PubMed ID: 26782845)
1. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
4. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
5. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
Raimondi A; Simeone N; Guzzo M; Maniezzo M; Collini P; Morosi C; Greco FG; Frezza AM; Casali PG; Stacchiotti S
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661185
[TBL] [Abstract][Full Text] [Related]
6. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
O'Halloran M; Boyd NM; Smith A
Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw.
Drozdzowska B
Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
[TBL] [Abstract][Full Text] [Related]
8. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
9. [Drug-induced osteonecrosis of the jaw - not just bisphosphonates].
Finkelshteyn A; Yarom N
Refuat Hapeh Vehashinayim (1993); 2017 Jan; 34(1):32-35, 72. PubMed ID: 30699493
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
11. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
12. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
13. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
[TBL] [Abstract][Full Text] [Related]
14. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
15. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
Ramírez L; López-Pintor RM; Casañas E; Arriba Ld; Hernández G
Oral Health Prev Dent; 2015; 13(5):385-93. PubMed ID: 25884045
[TBL] [Abstract][Full Text] [Related]
16. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
Zhang C; Shen G; Li H; Xin Y; Shi M; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
Spec Care Dentist; 2024; 44(2):530-541. PubMed ID: 37219080
[TBL] [Abstract][Full Text] [Related]
17. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
Yarom N; Lazarovici TS; Whitefield S; Weissman T; Wasserzug O; Yahalom R
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan; 125(1):27-30. PubMed ID: 29102242
[TBL] [Abstract][Full Text] [Related]
18. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
Liu FC; Luk KC; Chen YC
Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
[TBL] [Abstract][Full Text] [Related]
19. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
[TBL] [Abstract][Full Text] [Related]
20. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?
Colella A; Yu E; Sambrook P; Hughes T; Goss A
J Oral Maxillofac Surg; 2023 Feb; 81(2):232-237. PubMed ID: 36442534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
